Alnylam Pharmaceuticals
ALNY
$146.07
Share price
0.19%
Change (1 day)
-28.67%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) - Total debt
Total debt on the balance sheet as of December 2023 : $1.30 B
According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is $1.30 B. A company’s total debt is the sum of all current and non-current debts.
Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $1.30 B | -1.13% |
| 2022-12-31 | $1.32 B | 32.34% |
| 2021-12-31 | $0.99 B | 91.41% |
| 2020-12-31 | $0.52 B | 71.54% |
| 2019-12-31 | $0.30 B | 912.74% |
| 2018-12-31 | $30 M | 0% |
| 2017-12-31 | $30 M | -80% |
| 2016-12-31 | $0.15 B | |
| 2007-12-31 | $6.75 M | -26.03% |
| 2006-12-31 | $9.13 M | 23.54% |
| 2005-12-31 | $7.39 M | 2.69% |
| 2004-12-31 | $7.2 M | 287.36% |
| 2003-12-31 | $1.85 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $26.34 B | 1,918.40% | 🇨🇭 Switzerland |
 Sanofi SNY | $20.36 B | 1,460.23% | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | $2.70 B | 107.06% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $1.39 B | 7.00% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | $3.36 M | -99.74% | 🇺🇸 USA |
 OPKO Health
OPK | $0.32 B | -74.98% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $20.15 B | 1,443.83% | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | $0.11 B | -90.92% | 🇺🇸 USA |